# Treatment With Ribavirin for Patients With Metastatic Breast Cancer

> **NCT01056757** · PHASE1,PHASE2 · TERMINATED · sponsor: **Jewish General Hospital** · enrollment: 4 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01056757
- **Lead sponsor:** Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study closed because of new overlapping study with ribavirin.
- **Last updated:** 2015-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01056757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01056757, "Treatment With Ribavirin for Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01056757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*